Koers Celladon Corp Nasdaq
Aandelen
US15117E1073
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 13,48 12,61 | Omzet 2023 | 15,77 14,75 | Marktkapitalisatie | 9,96 mln. 9,32 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -96 mln. -89,77 mln. | Nettowinst (verlies) 2023 | -75 mln. -70,14 mln. | EV/omzet 2022 | -836.796 x |
Nettoliquiditeiten 2022 | 63,29 mln. 59,19 mln. | Nettoschuld 2023 | 15,36 mln. 14,36 mln. | EV/omzet 2023 | 1.605.487 x |
K/w-verhouding 2022 |
-0,51
x | K/w-verhouding 2023 |
-0,13
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 85,23% |
Recentste transcriptie over Celladon Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
James Vollins
CMP | Compliance Officer | 55 | 13-04-23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 18-07-22 | |
Thomas Dietz
CHM | Chairman | 60 | 22-03-16 |
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,13% | 46,93 mld. | |
+37,49% | 39,08 mld. | |
-8,73% | 38,48 mld. | |
+28,09% | 31,01 mld. | |
-12,26% | 26,14 mld. | |
+10,57% | 25,88 mld. | |
+45,05% | 14,15 mld. | |
+32,23% | 12,53 mld. | |
-6,56% | 11,36 mld. |